Arrowhead’s multibillion-dollar deal with Sarepta is still in place; Pharvaris’ $175M

Plus, news about ANI, Genentech, Telix and Madrigal: Arrowhead’s partnership with Sarepta Therapeutics is business as usual: Amid the blistering pace of updates from Sarepta over the past week, Arrowhead Pharmaceuticals sought to get ahead ...